Analysis of HMGB1 gene expression and prognostic value in colon tumors based on Oncomine and TCGA datasets

doi:10.3877/cma.j.issn.2095-3224.2020.06.003

Abstract

Abstract:

Objective

To study the expression and prognosis of high mobility group protein B1 (HMGB1) gene in colon tumor.

Methods

The HMGB1-related data of 2 191 colon tumor patients were mined from Oncomine and TCGA datasets. The Mann-Whitney U test was used to compare the differential expression of HMGB1 between colonic adenoma and carcinoma, left and right half colon cancer, carcinoma in situ and infiltrating cancer, mucinous adenocarcinoma and other pathological types, with lymph node metastasis and without lymph node metastasis, with distant metastasis and without distant metastasis of colon cancer. Then the Kaplan Meier survival curve was drawn.

Results

HMGB1 gene was highly expressed in colon cancer tissues and adenoma tissues than in normal colon tissues (P<0.001), higher in colon cancer tissues than in colonic adenoma tissues, overexpressed in left colon cancer compared to right colon cancer (P<0.05), lower in mucinous adenocarcinoma of the colon than other pathological tissue types (P<0.05), overexpressed in infiltrating carcinoma compared with carcinoma in situ (P<0.001), overexpressed in patients with regional lymph node metastasis (P<0.05), and overexpressed in metastatic colon cancer than non-metastatic colon cancer (P<0.05). Overexpression of HMGB1 gene indicates a higher 5-year survival rate (P=0.011), especially for female patients (P=0.006).

Conclusion

HMGB1 gene can be used as a marker to evaluate the invasion depth, lymphatic metastasis, distant metastasis and prognosis of colon cancer.

Key words: Colonic neoplasms, HMGB1, Oncomine, TCGA, Survival analysis

Xianhao Su, Huipeng Wang, Wenjie Chen, Jiamen Shen, Tao Ye, Yuankun Cai. Analysis of HMGB1 gene expression and prognostic value in colon tumors based on Oncomine and TCGA datasets[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(06): 552-557.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.06.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I06/552

Figures/Tables 3

References 26

[26]	李增军，王海鹏，宋宝, 等. 高迁移率族蛋白1在结肠癌组织中的表达及临床意义 [J]. 中华胃肠外科杂志, 2015, 18(6): 616-619.
[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68: 394-424.
[2]	Yang CA, Huang HY, Chang YS, et al. DNA-sensing and nuclease gene expressions as markers for colorectal cancer progression [J]. Oncology, 2017, 92(2): 115-124.
[3]	Ekanayaka SA, McClellan SA, Peng X, et al. HMGB1 antagonist, box A, reduces TLR4, RAGE, and inflammatory cytokines in the cornea of P. aeruginosa-infected mice [J]. J Ocul Pharmacol Ther, 2018, 34(10): 659-669.
[4]	Schade GR, Wang YN, D'Andrea S, et al. Boiling histotripsy ablation of renal cell carcinoma in the eker rat promotes a systemic inflammatory response [J]. Ultrasound Med Biol, 2018, 45(1): 137-147.
[5]	Li S, Gu H, Huang Y, et al. Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling [J]. Cell Cycle, 2018, 17(19-20): 2349-2359.
[6]	Wang L, Kang FB, Wang J, et al. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway [J]. Anticancer Drugs, 2019, 30(3): 225-232.
[7]	Liu Y, Du M, Song Y, et al. NAC1/HMGB1 signaling pathway is associated with epithelial-mesenchymal transition, invasion, and metastasis of lung cancer cell line [J]. Ann Clin Lab Sci, 2018, 48(5): 559-564.
[8]	Sun E, Liu K, Zhao K, et al. Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression [J]. Cancer Biol Ther, 2019, 20(3): 307-320.
[9]	Williams HL, Walsh K, Diamond A, et al. Validation of the oncomine focus panel for next-generation sequencing of clinical tumour samples [J]. Virchows Arch, 2018, 473(4): 489-503.
[10]	Notterman DA, Alon U, Sierk AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays [J]. Cancer Res, 2001, 61(7): 3124-3130.
[11]	Sabates-Bellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas [J]. Mol Cancer Res, 2007, 5(12): 1263-1275.
[12]	Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability [J]. PLoS One, 2010, 5(10): e13091.
[13]	Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays [J]. Proc Natl Acad Sci USA, 1999, 96(12): 6745-6750.
[14]	Gaedcke J, Grade M, Jung K, et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas [J]. Genes Chromosomes Cancer, 2010, 49(11): 1024-1034.
[15]	Hong Y, Downey T, Eu KW, et al. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics [J]. Clin Exp Metastasis, 2010, 27(2): 83-90.
[16]	Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer [J]. Genome Biol, 2007,8(7): R131.
[17]	Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer [J]. Int J Cancer, 2007, 121(9): 2005-2012.
[18]	Kurashina K, Yamashita Y, Ueno T, et al. Chromosome copy number analysis in screening for prognosis-related genomic regions in colorectal carcinoma [J]. Cancer Sci, 2008, 99(9): 1835-1840.
[19]	Notterman DA, Alon U, Sierk AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays [J]. Cancer Res, 2001, 61(7): 3124-3130.
[20]	Yang H, Wang H, Chavan SS, et al. High mobility group box protein 1 (HMGB1): The prototypical endogenous danger molecule [J]. Mol Med, 2015, 21 (Suppl 1): S6-S12.
[21]	徐荣辉，穆向明. 左半结肠癌与右半结肠癌差异性研究进展 [J/CD]. 心血管外科杂志(电子版), 2019, 8(1): 194-195.
[22]	Taguchi A, Blood DC, del Toro G, et al.Blockade od RAGE-amphoterin signalingsuppresses tumour growth and metastasis [J]. Nature, 2000, 405(6784): 354-360.
[23]	Sasahira T, Kirita T, Oue N, et al. HMGB1-inducible melanoma inhibitoryactivity is associated with nodal metastasisand lymphangiogenesis in oral squamouscell carcinoma [J]. Cancer Sci, 2008, 99 (9) :1806-1812.
[24]	Treutiger CJ, Mullins GE, Johansson AS, et al.High mobility groop1B-boxmediates activation of human endothelium [J]. J Intern Med, 2003, 254(4): 375-385.
[25]	闻莲，何雪晴，钱一可, 等. HMGB1在抗肿瘤免疫发生中的作用[J].生命的化学, 2020, 40(4): 483-489.

Please choose a citation manager

Content to export